Michael Jensen

Chief Therapeutics Officer

Michael Jensen, MD, is a professor of hematology-oncology at the University of Washington School of Medicine. He is member of the clinical division in the Program in Immunology at Fred Hutchinson Cancer Center. Dr. Jensen holds the Janet and Jim Sinegal Endowed Chair in Pediatric Solid Tumor Research in Honor of Korey Rose.

Dr. Michael Jensen graduated from the University of Pennsylvania School of Medicine then completed training in Pediatric Hematology and Oncology at the University of Washington/Fred Hutchinson Cancer Center. His laboratory work began under the mentorship of Dr. Philip Greenberg, Program Head in Immunology, Fred Hutch and focused on the immunobiology of tumor-specific T cells. Following completion of his fellowship, Dr. Jensen joined the faculty at the City of Hope National Medical Center, where he built a translational research program integrating gene therapy and cellular immunotherapy for cancer. This program grew into the Department of Cancer Immunotherapeutics & Tumor Immunology within the Beckman Research Institute and was incorporated into the institution's NCI-Comprehensive Cancer Center as the Cancer Immunotherapeutics Program with Dr. Jensen as its leader. During his tenure at City of Hope, Dr. Jensen's research program placed a strong emphasis on bench-to-bedside translational research and resulted in seven FDA-authorized Investigational New Drug Applications covering first-in-human applications of adoptive transfer of genetically engineered T cells having redirected tumor specificity for lymphoma, neuroblastoma and malignant gliomas. In 2010, Dr. Jensen joined the University of Washington School of Medicine faculty as a Professor of Pediatrics and is the founding director of the Ben Towne Center for Childhood Cancer Research. He holds the Janet and Jim Sinegal endowed chair in pediatric cancer research. Dr.

Talks About
#biotechnology #startups

Preferred Locations
#Northamerica